Evaluation and follow-up strategies for superficial bladder cancer.
about
Intravesical gemcitabine for non-muscle invasive bladder cancerIntravesical gemcitabine for non-muscle invasive bladder cancerAdvances in intravesical therapy for the treatment of non-muscle invasive bladder cancer (Review).Predicting recurrence and progression of non-muscle-invasive bladder cancer in Korean patients: a comparison of the EORTC and CUETO models.Urinary bladder: normal appearance and mimics of malignancy at CT urography.Epigenetic regulation of Elf5 is associated with epithelial-mesenchymal transition in urothelial cancer.Impact of proteomics on bladder cancer research.Surveillance and treatment of non-muscle-invasive bladder cancer in the USA.GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy.Pharmacogenetic association between XRCC1 polymorphisms and improved outcomes in bladder cancer patients following intravesical instillation of epirubicin.The impact of advanced proteomics in the search for markers and therapeutic targets of bladder cancer.Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer.Germline prognostic markers for urinary bladder cancer: obstacles and opportunities.Epigenetic biomarkers in urothelial bladder cancer.Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression.Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation.Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006.Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy.Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients.Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience.Developing proteomic biomarkers for bladder cancer: towards clinical application.Association of KLK5 overexpression with invasiveness of urinary bladder carcinoma cells.Impact of diabetes mellitus on recurrence and progression in patients with non-muscle invasive bladder carcinoma: a retrospective cohort study.Comparison of surveillance strategies for low-risk bladder cancer patients.Bladder cancer and smoking. Part 2: diagnosis and management.Second Opinion Expert Pathology Review in Bladder Cancer: Implications for Patient Care.Spray Dried Chitosan Microparticles for Intravesical Delivery of Celecoxib: Preparation and Characterization.The use of water-soluble mucoadhesive gels for the intravesical delivery of epirubicin to the bladder for the treatment of non-muscle-invasive bladder cancer.Validation of Urine-based Gene Classifiers for Detecting Bladder Cancer in a Chinese Study
P2860
Q24203884-011E46F5-F51F-440B-A009-9CD87231BFE1Q24236635-A1BCAB7F-0583-4C62-A307-6277BB2A9DE1Q33933049-1EC7356F-ADCD-4AE4-8AE7-0D7545414B61Q34346848-B876B99F-F9F2-4777-AB5F-83935B76C673Q35495982-291979D1-150E-4877-B01A-9B9148ACD935Q35550740-0663A13E-0270-453E-B5CB-9D3845C71E7EQ35785226-751F0561-0FC5-4691-B867-B7A36310ECB2Q35977496-4A9BE450-043C-4F4D-96A7-7CB0F2C1026EQ36044627-038B4A2C-D112-4170-907D-468CB7FEFF1DQ36046527-EC525B65-E7FB-426B-8307-75B0417F9D02Q36323508-5C84F5C0-C293-4356-962C-8E98930AD35BQ36600567-52D75480-7596-4695-AE03-A8627A582DF5Q37298808-CE618A3F-DAB9-4BA8-9085-EB7EC0CA78C3Q37451558-F5956F71-2B36-45B6-9B4B-82484FD1C2BDQ37553390-F65BD92F-123C-4728-A80E-A87DC3264AC7Q37564393-503D2017-FD26-48DC-AF8F-0A71E001C5E4Q37659604-1E94D393-5769-4FED-B34A-3648065C6815Q37705271-09844BB5-882A-4265-8E68-03BD68DE0916Q37998119-38D75761-90FB-4DA5-8635-2F55D1A46C6BQ38002454-F8D2E85F-696D-4436-9A93-1A81E33A6B00Q38511509-94E4AE64-66FA-4BDC-A1DC-0FD343A0B2D4Q40141225-23BB741E-A4E2-4EE6-81EA-A513672B748AQ43747872-64633C6C-5D3C-4E7D-A59E-B7A647ADD88EQ44866563-DA852149-3AEC-41F9-BE62-1A55AC714B61Q46272285-BBE29E0B-A231-4E7B-A269-93DDC2AF5DC2Q47987483-BB613E47-A82E-461F-B838-84EA481794DDQ51310226-068EDD16-E4A9-4CD9-83F9-79B3FE118E47Q53207774-373DA88F-D4F7-496E-A7FD-AFC5D6B45590Q58798340-5C547D2E-80F5-411B-837F-93B2C1570BA0
P2860
Evaluation and follow-up strategies for superficial bladder cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Evaluation and follow-up strategies for superficial bladder cancer.
@ast
Evaluation and follow-up strategies for superficial bladder cancer.
@en
type
label
Evaluation and follow-up strategies for superficial bladder cancer.
@ast
Evaluation and follow-up strategies for superficial bladder cancer.
@en
prefLabel
Evaluation and follow-up strategies for superficial bladder cancer.
@ast
Evaluation and follow-up strategies for superficial bladder cancer.
@en
P1476
Evaluation and follow-up strategies for superficial bladder cancer
@en
P2093
S Machele Donat
P304
P356
10.1016/S0094-0143(03)00060-0
P50
P577
2003-11-01T00:00:00Z